This content is machine translated Multiple Myeloma Approval of daratumumab in Switzerland At the beginning of this year, the first active immunotherapy directed against CD38 in refractory multiple myeloma was approved in Switzerland. The data from the two studies MMY2002 (SIRIUS) and…
